Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 4/20 | 0.41 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.39 |
| ▸ | OXTR | P30559 | 1/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9948241 | 0.94 | APLNR (0.38) | APLNRAVPR2OXTRAVPR1AACHE | |
| SCHEMBL9948279 | 0.91 | APLNR (0.39) | APLNRACHE | |
| SCHEMBL9948175 | 0.91 | APLNR (0.40) | APLNRAVPR2OXTRAVPR1A | |
| SCHEMBL504759 | 0.91 | APLNR (0.42) | APLNRACHE | |
| SCHEMBL9948111 | 0.90 | APLNR (0.41) | APLNRAVPR2OXTRAVPR1AACHE | |
| SCHEMBL27932357 | 0.87 | AVPR2 (0.40) | APLNRAVPR2OXTRAVPR1AACHE | |
| SCHEMBL15869618 | 0.85 | APLNR (0.38) | APLNRACHE | |
| SCHEMBL9948152 | 0.84 | APLNR (0.36) | APLNR | |
| SCHEMBL9948112 | 0.84 | SLC33A1 (0.46) | — | |
| SCHEMBL504366 | 0.84 | ACHE (0.40) | APLNRACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315493-B2 | Phenylpyridine derivative and drug containing same | KOWA COMPANY, LTD. (JP) | 2016-04-19 | — | — | US | disclosed |
| EP-2484675-B1 | NOVEL PHENYLPYRIDINE DERIVATIVE AND MEDICINAL AGENT COMPRISING SAME | KOWA CO (JP) | 2014-11-05 | — | — | EP | disclosed |
| CN-102639527-B | Novel phenylpyridine derivative and medicinal agent comprising same | KOWA CO | 2014-11-05 | — | — | CN | disclosed |
| US-8778954-B2 | Phenylpyridine derivative and medicinal agent comprising same | KOWA COMPANY, LTD. (JP) | 2014-07-15 | — | — | US | disclosed |
| EP-2687523-A1 | NOVEL PHENYLPYRIDINE DERIVATIVE AND DRUG CONTAINING SAME | Kowa Company Ltd. (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-20140011823-A1 | NOVEL PHENYLPYRIDINE DERIVATIVE AND DRUG CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2014-01-09 | — | — | US | disclosed |
| CN-103459380-A | Novel phenylpyridine derivative and medicine containing the same | KOWA CO | 2013-12-18 | — | — | CN | disclosed |
| CN-102639527-A | Novel phenylpyridine derivative and medicinal agent comprising same | KOWA CO | 2012-08-15 | — | — | CN | disclosed |
| EP-2484675-A1 | NOVEL PHENYLPYRIDINE DERIVATIVE AND MEDICINAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-20120165353-A1 | NOVEL PHENYLPYRIDINE DERIVATIVE AND MEDICINAL AGENT COMPRISING SAME | KOWA COMPANY, LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011823-A1 | NOVEL PHENYLPYRIDINE DERIVATIVE AND DRUG CONTAINING SAME | AGTR2, AGTR1, PPARD | APLNR 331/4885AVPR2 257/4885OXTR 643/4885 |
| US-20120165353-A1 | NOVEL PHENYLPYRIDINE DERIVATIVE AND MEDICINAL AGENT COMPRISING SAME | AGTR2, AGTR1, PPARD | APLNR 620/4885AVPR2 111/4885OXTR 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.